Wells Fargo’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-91,540
| Closed | -$2.52M | – | 7898 |
|
|
2021
Q2 | $2.52M | Sell |
91,540
-18,766
| -17% | -$369K | ﹤0.01% | 3481 |
|
|
2021
Q1 | $1.82M | Sell |
110,306
-71,601
| -39% | -$1.63M | ﹤0.01% | 3781 |
|
|
2020
Q4 | $3.35M | Buy |
181,907
+49,890
| +38% | +$893K | ﹤0.01% | 3085 |
|
|
2020
Q3 | $1.8M | Buy |
132,017
+37,572
| +40% | +$579K | ﹤0.01% | 3403 |
|
|
2020
Q2 | $1.69M | Buy |
94,445
+72,999
| +340% | +$1.1M | ﹤0.01% | 3390 |
|
|
2020
Q1 | $214K | Buy |
21,446
+5,656
| +36% | +$46.3K | ﹤0.01% | 4643 |
|
|
2019
Q4 | $129K | Buy |
15,790
+429
| +3% | +$3.96K | ﹤0.01% | 5185 |
|
|
2019
Q3 | $152K | Buy |
15,361
+829
| +6% | +$7.83K | ﹤0.01% | 5120 |
|
|
2019
Q2 | $183K | Buy |
14,532
+3,393
| +30% | +$35.8K | ﹤0.01% | 5018 |
|
|
2019
Q1 | $114K | Buy |
11,139
+160
| +1% | +$1.23K | ﹤0.01% | 5091 |
|
|
2018
Q4 | $82K | Sell |
10,979
-262,334
| -96% | -$1.92M | ﹤0.01% | 5374 |
|
|
2018
Q3 | $2.73M | Buy |
273,313
+163,313
| +148% | +$1.9M | ﹤0.01% | 3140 |
|
|
2018
Q2 | $1.39M | Buy |
+110,000
| New | +$1.33M | ﹤0.01% | 3743 |
|
Wells Fargo's TBIO Position: Q3 2021 in Review
Wells Fargo sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 91,540 shares — an estimated $2.52M sold.
Wells Fargo first reported a position in TBIO in Q2 2018 and held it in 13 quarters. The position peaked at $3.35M in Q4 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Wells Fargo reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Wells Fargo sold 91,540 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $2.52M.
- Wells Fargo first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- Wells Fargo's Translate Bio, Inc. Common Stock position peaked at $3.35M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Wells Fargo's 13F filing for Q3 2021, filed 15 Nov 2021.